chrisvoncsefalvay/vaers-outcomes huggingface dataset:
scheduled to get an allergy shot 12 days after first dose of COVID vaccine; This is a spontaneous report from a contactable consumer (patient)  A male patient of unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection,) on 10Feb2021  at single dose via an unspecified route of administration  for COVID-19 immunization. Relevant medical history and concomitant medications were not reported. Patient Since 22Feb2021 patient was getting allergy shots 12 days after his first dose of vaccine; Second dose of vaccine was scheduled until 03Mar2021. Patient was asking if she have to wait 7 days in between or 14 days (as reported). At the time of the reporting.The patient was treated due to the event. At the time of the reporting event outcome was unknown.  No follow-up attempts are possible, information about lot/batch number cannot be obtained.
Sinus tachycardia, paroxysmal atrial tachycardia, activity intolerance- heart rate 150's within minutes of injection. Random spells for 4 days. Heart rate is trending down with occasional spike. Activity intolerance continues. Contacted cardiologist and was told to take an extra dose of metoprolol. Continues to double the dose for 4 days. Today is Day 5 and will assess the need later, for this morning I took the regular prescribed dose.
The patient presented with Urticaria with pruritus. She broke out in some urticaria scattered over her arms and torso.  She does have the itching. Except for getting the COVID vaccine, there is been nothing new at all in her diet or environment as far as mom is aware. She has not had any sore throats, she has not had any fevers, she has not had coughing, and she does not have a complaint of shortness of breath. She is not having any belly pain. She was given benadryl and prednisone
Information has been received from a registered nurse concerning a 26 year old female with no known medical history and drug reactions/allergies, who on 05-AUG-2008, was vaccinated with GARDASIL vaccine (yeast) (Lot # 660553/0070X), 0.5 ml, via intramuscularly route. There was no concomitant medication. The physician reported that on 08-AUG-2008, the patient had site pain injection after she was vaccinated with GARDASIL vaccine (yeast). The physician also reported that a few hours later, on 08-AUG-2008, the patient developed nasal congestion, dizziness and tingling in the same arm as the injection site. The patient was treated with OTC BENADRYL. on 06-AUG-2008, the patient had recovered. The patient sought medical attention at physician's office. Additional information has been requested.
A report has been received from a Health Professional concerning a, subject of unknown gender, who had been receiving FLUMIST, 0.2 Millilitres, once/single administration. FLUMIST started on an unknown date. HCP explained that expired FLUMIST given to patient. FLUMIST expired 3 days before. The outcome of the event of expired FLUMIST given to patient is unknown. The report was considered to be non-serious.
Headache; Hot flashes; Blood pressure high; Sinus infection; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 86 year-old patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 86 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose), for COVID-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 2021, outcome "unknown", described as "Headache"; HOT FLUSH (non-serious) with onset 2021, outcome "unknown", described as "Hot flashes"; HYPERTENSION (non-serious) with onset 2021, outcome "unknown", described as "Blood pressure high"; SINUSITIS (non-serious) with onset 2021, outcome "unknown", described as "Sinus infection". Relevant laboratory tests and procedures are available in the appropriate section. Additional information: Patient had head ache and hot flashing ever since patient got second vaccine and it was now going into 6 weeks . Does anybody had reported crazy things like that. Patient had hot flushing Patient may be 86 years old so patient never had hot flushes when patient changed life later on now.  Patient was just wondering if anybody else have reported the things such as headache and hot flushing. They did an MRI because patient did not think it was the best thing. patient did MRI and they said oh patient had a sinus infection (captured conservatively). Patient did some washing for sinus infection then patient experienced high blood pressure which patient never had. So all these things happened to patient ever since the vaccine and patient was wondering if anybody else have reported things like that.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from a registered nurse concerning a female patient who on 18-MAY-2007 was vaccinated with a first dose of GARDASIL (route and lot numbers not reported). On 30-JUL-2007 the patient was vaccinated with a second dose of GARDASIL (route and lot numbers not reported). On 15-FEB-2008 the patient was vaccinated with a third dose of GARDASIL (route and lot numbers not reported). There was no concomitant medication, the patient did not receive other vaccines on any of the days she received GARDASIL. "Recently" (date unknown), the patient "had PAP smear done by her obstetrician-gynecologist, the PAP smear was abnormal and the patient would have an upcoming biopsy". The patient did not receive any treatment for the event. The patient sought medical attention by office visit. The nurse noted that the patient had not recovered. Follow up information has been received from a registered nurse concerning a 17 year old female student patient with no known drug allergies and no illness at time of vaccination who on 18-MAY-2007, was vaccinated with the first dose of GARDASIL intramuscularly in the left deltoid (lot number 656049/0187U). On 30-JUL-2007, the patient was vaccinated with the second dose of GARDASIL intramuscularly in the right deltoid (lot number 657737/0522U). On the morning at 11 A.M. of 15-FEB-2008, the patient was vaccinated with the third dose of GARDASIL intramuscularly in the left deltoid (lot number 659055/1522U). In April 2011, the patient had a PAP smear done at obstetrician/gynecologist. Smear and further test were done. On 19-MAY-2011, a colposcopy procedure would had be done. The mother of the patient called to the nurse and reported that report from obstetrician/gynecologist on the colposcopy was negative. At the time of the report the outcome of the patient was unknown. PAP smear abnormal was considered to be an other important medical event by the registered nurse because required medical/surgical intervention. Additional information has been requested.
A non-serious report of "FLUMIST was administered to a 52-year-old person" was received from a health care professional concerning a 52-year-old male. The patient's medical history and concomitant medications were not reported. The patient was inadvertently administered FLUMIST on 01-Nov-2009. There was no adverse event associated with this event; therefore, treatment and causality assessments are not applicable, and the event is considered resolved.
pt recv vax 15JUL98 & MOC reported 36hr later pt devel a fine rash on torso & head;reports rash was red & itchy;upon exam 22JUL98 had a fine raised rash on torso & face w/mild erythema under neck & axilla;pt referred to allergy;
Patient started feeling tingling on his left arm immediately after the vaccine. Patient then started feeling like the room was spinning, nausea, really cold, and started getting pale. Clinical staff responded by the taking the patient's vitals (138/72 BP, 81 bpm, 98% 02) and water was provided. Patient stated that he didn't have anything to eat. Wife provided him a sugar candy and a sugar snack. Patient stated he was feeling better at 10:45am. 2nd vital sign (132/82, 83 bpm, 98% o2).
Received Pfizer booster 10/5 in the morning, later in the afternoon started to experience nausea, dizziness, lightheadedness, weakness, chills, runny nose, cough, left arm sore at injection site.
Within two hours of injection, headache and fever symptoms with body aches for appoximately 56 hours. Approximately 40 hours after injection, noticable drooping of right side of face, which resolved 90% after 24 hours; doctor assessment was that this was likely a temporary case of Bell's Palsy.
Day of injection:  Slight headache about 90 minutes after injection.  Came and went.  No medicine taken. Wave of nausea lasting about 15 minutes later in the evening.  2nd day:  Arm soreness.  Feeling in my chest as though I needed to take a deep breath, on and off throughout the day.  Heart rate fine, blood pressure good (125/70 average), blood oxygen 97-99 all day, evening.  3rd day:   arm soreness diminished.  No other side effects.
Rash in her face after the vaccine; More than 36 days after the first dose without receiving the second dose; This spontaneous case was reported by a physician and describes the occurrence of RASH (Rash in her face after the vaccine) and PRODUCT DOSE OMISSION ISSUE (More than 36 days after the first dose without receiving the second dose) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (Rash in her face after the vaccine) and PRODUCT DOSE OMISSION ISSUE (More than 36 days after the first dose without receiving the second dose). At the time of the report, RASH (Rash in her face after the vaccine) and PRODUCT DOSE OMISSION ISSUE (More than 36 days after the first dose without receiving the second dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Relevant concomitant product usage were not reported by the reporter. No treatment details were added.
Side of left thigh pain from hip to knee; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207) via an unspecified route of administration in the left arm on an unknown date in Mar2021 at 15:00 (at the age of 56-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0161) via an unspecified route of administration in the left arm on 13Apr2021 at 15:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had seasonal allergies. Concomitant medications included fluticasone propionate, salmeterol xinafoate (ADVAIR), montelukast (MANUFACTURER UNKNOWN), fish oil (MANUFACTURER UNKNOWN) and vitamin d nos (MANUFACTURER UNKNOWN); all taken for unknown indications from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received codeine (MANUFACTURER UNKNOWN) taken for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date in Mar2021, next day after first dose, the patient experienced side of left thigh pain from hip to knee. On 16Apr2021 at 18:00, the patient experienced same pain, only the pain began 3 days after the second shot. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left thigh pain from hip to knee was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
pt recvd vax & began running temp of 104 ax; exp body jerks according to mom of child-not full convusl; mom called MD who told her not to worry unless pt had full convuls;
red, swollen, warm to touch (15x11cm.  Pepcid and Zyrte
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021 at 2:30 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 03-Apr-2021 at 2:30 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 27.41 for dose administered on 3-Apr-2021 No concomitant medications were reported. Batch number 030B21A underwent temperature excursion on 3-Apr-2021 with temperature 34 degrees Fahrenheit from 09:00 AM. This vial was moved to fridge on 30-Mar-2021 and beyond use date for the vial was reported as 29-Apr-2021. Product moved to clinic on 3-Apr-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour. No treatment medications were reported
Patient came to pharmacy today stating she went to ER suffering from pain at injection site & in lower left arm & tingling & numbness in left hand that had not subsided since she received the flu shot. She went to the ER because the symptoms mimicked were similar to a heart attack (post MI x 2) ER doctor ruled out not an MI but told pt the needle hit a nerve bundle. Pt did not seek further tx & did not notify doctor.
This spontaneous report was received from a physician, via company representatives, and refers to a patient of unknown age and gender. Information about the patient's pertinent medical history, drug reactions/allergies and concomitant medications was not reported. On 27-OCT-2014, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23, "10PK-0.5ml SD-PFS LLok wTip" which had the lot # K009874 with expiration date 19-MAR-2016, (dosage number and route of administration were not reported). Nonetheless, no adverse effects were reported and no product quality complaint was involved. On an unspecified date, the vaccine experienced a temperature excursion of 47 F (8.333333333 Celsius) for 40 hours (highest recorded temperature). The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator (R)". This is one of the several reports received from the same reporter. Additional information has been requested.
24SEP96 pt recv vax 3PM onset w/pain & redness;26SEP96 lump, warmth, cold compress, Ibuprofen, Atarax;30SEP96 itching & pain went to ER tx w/ATB;8OCT96 much better lump 1" in diameter;no pain or redness;
Patient presented with redness, swelling, and warmth at the injection site on 9/1/2017 at 10:15AM. She was seen by an NP who diagnosed cellulitis and prescribed IV ceftriaxone 2 gram. This was given during her visit. Follow up call on 9/7/2017 indicates that cellulitis had resolved.
This spontaneous report as received from a physician refers to an unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with the improperly stored (above 46F but below 77F with a maximum temperature of 50F for 3 hours 15 minutes plus a second excursion between 32F and 36F, to 35 F for 3.5 minutes) doses of ROTATEQ (orally, lot # M026315, expiration date 26-JAN-2018; dose was not reported) for prophylaxis. No adverse effects and no previous excursion were reported. The call was made because of a data logger. This is one of two reports received from the same reporter. Additional information is not expected as the reporter did not wish to be contacted. Sender's Comments: US-009507513-1702USA004609.
pain at the injection site; redness at the injection site; rash at the injection site; feeling achy; felt feverish; This case was reported by a nurse via call center representative and described the occurrence of injection site pain in a 64-year-old female patient who received Herpes zoster (Shingrix) (batch number D7797, expiry date 9th July 2021) for prophylaxis.   On 5th November 2019, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. In November 2019, less than a week after receiving Shingrix, the patient experienced injection site pain, injection site erythema, injection site rash, pain and feeling hot. In November 2019, the outcome of the injection site pain, injection site erythema, injection site rash, pain and feeling hot were recovered/resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema, injection site rash, pain and feeling hot to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and had feeling achy, feverish, pain at the injection site, redness at injection site.  The patient also said that she had a 4 x 6 inch rash at the injection site. The nurse called back the patient at the time of reporting and patient said that the symptoms were gone.
experiencing COVID-19 symptoms; tested positive for COVID-19 infection; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (tested positive for COVID-19 infection) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Feb-2021, the patient experienced COVID-19 (tested positive for COVID-19 infection) with UNEVALUABLE EVENT (experiencing COVID-19 symptoms). At the time of the report, COVID-19 (tested positive for COVID-19 infection) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Feb-2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were reported. No treatment medications were reported.
headache, nausea, fatigue, shortness of breath- started two days after vaccine and lasted about 5 days.  Was tested for COVID19- results were negative
After approx. 10 hours after injection, my 1 month old baby refused to drink breast milk from my breast. He would scream and reject the milk. I substituted older, frozen breast milk instead, which he drank without issue. He also slept 4 hours longer than normal, and was irritable/fussy for 2 days following. He returned to drinking breast milk from my breast 2 days after the injection.
Dependent child of military personnel came in contact with towel used by parent to dry vaccine site after shower. Child presented to ED with fever and red blanching, flat lacy rash. No vesicles. Discharged home with flu by pediatrician.
headache; body ache and chills; body ache and chills; This is a spontaneous report from a contactable physician received via Pfizer Sales Representative.   An 18-year-old female patient received meningococcal group b rlp2086 (TRUMENBA) at single dose, and influenza vaccine (Quadravalent flu vaccine, Sanofi), both in right arm on 27Oct2020 for immunisation.  The patient medical history and concomitant medications were not reported. The patient previously received a dose of TRUMENBA at single dose and FLU vaccine, both in right arm in 2019 for immunization and experienced neck stiffness headache and swelling in the arm. The patient experienced headache, body ache and chills on 27Oct2020. The outcome of headache, body ache and chills were recovered after one day in Oct2020. Patient was seen on the 29Oct2020 and physician confirmed to the reporter.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
patient cannot swallow pills; Muscle weakness/weakness and a collapse; shooting pains/severe pain in the arm muscle where the shot was given; Nausea; fatigue; sore to the touch and all muscles that are noted below; Knee joint pain; shooting pains progressed to lower arm, then to thighs/pains still in upper left calf; This is a spontaneous report from contactable consumer (patient). A 73-year-old non-pregnant female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6205), via an unspecified route of administration in the right arm on 06Mar2021 at 13:45 as a single dose for COVID-19 immunisation. The patient's medical history was non-significant. Prior to the vaccination. The patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. No allergies to medications, food, or other products. Concomitant medications included blood pressure medication, triamcinolone acetonide (NASACORT), clarithromycin (CLARITIN) (within two weeks of vaccination as reported) for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Mar2021 at 16:00, the patient experienced severe pain in the arm muscle where the shot was given and sore to the touch and all muscles that are noted below. Had shooting pains progressed to lower arm, then to thighs, then to knee joints which had a weakness and a collapse. Experienced fatigue and some nausea. Pains are now in the 12th. day and pains still in upper left calf and knee. Pain levels are 6-7 and limiting most all normal daily activities. On 18Mar2021, the patient cannot swallow pills to take Ibuprofen or Tylenol. Since they are time release, patient cannot cut or crush. The patient took acetylsalicylic acid (ASPIRIN) with little relief. The patient read the second symptoms are greater and patient cannot take another two weeks more pain. It seems these issues are lasting more than 12 days and am concerned with them. The patient contacted her doctor. The clinical outcomes of all the events was not recovered.   No follow-up attempts are needed. No further information is expected.